Childhood Chronic Inflammatory Demyelinating Polyneuropathy With Nonuniform Pathologic Features

Luan, Xinghua; Zheng, Riliang; Chen, Bin; Yuan, Yun

doi:10.1016/j.pediatrneurol.2010.04.001

Cited by 11 publications

(15 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other oculomotor symptoms comprised afferent pupillary defect and partial right VIth nerve palsy, ptosis, abduction deficit and unilateral tonic pupillary dilatation (20,33). Bulbar disorders resulted in dysphagia, and mastication, hypophonia and lingual fasciculations (31,34,35). Generalized facial weakness and dysarthria have also been shown (30)(31)(32)34).…”

Section: Clinical Manifestationsmentioning

confidence: 99%

“…Exceptually, facial weakness was found in 20-33% of the children (21). In some studies, cranial nerve dysfunction has been described (20,25,30,31). In these children, diplopia has been a common feature (25,(30)(31)(32).…”

Section: Clinical Manifestationsmentioning

confidence: 99%

“…In some studies, cranial nerve dysfunction has been described (20,25,30,31). In these children, diplopia has been a common feature (25,(30)(31)(32). Other oculomotor symptoms comprised afferent pupillary defect and partial right VIth nerve palsy, ptosis, abduction deficit and unilateral tonic pupillary dilatation (20,33).…”

Section: Clinical Manifestationsmentioning

confidence: 99%

“…Bulbar disorders resulted in dysphagia, and mastication, hypophonia and lingual fasciculations (31,34,35). Generalized facial weakness and dysarthria have also been shown (30)(31)(32)34). Sensorineural deafness was defined in one patient (35).…”

Section: Clinical Manifestationsmentioning

confidence: 99%

“…As a first-line therapy, oral prednisone is usually administered at a dose of 1 -2 mg/kg/day in the initial four to six weeks, then reduced over the next four to six weeks (45,64), or even by tapering over 3 -6 months.6 Interval therapy (2 mg/kg/day for 3 -8 days, repeated every four weeks) and also alternating therapy (2 mg/kg/alternate day) have been designated (58,65). In some patients, high-dose 'pulse' methylprednisolone therapy (15 -20 mg/kg/day for three days) was intravenously administered before the origination of oral prednisone therapy (31,33,48). The side effects of long-term use of corticosteroids in children include osteopenia, growth suppression, cataract, immune compromise, hypertension, hyperglycemia, gastrointestinal symptoms and weight gain (45).…”

Section: Prednisonementioning

confidence: 99%

See 4 more Smart Citations

Chronic Inflammatory Demyelinating Polyneuropathy in Children: A Review of Clinical Characteristics and Recommendations for Treatment

Karimi¹,

Sharifi²,

Zarvani³

et al. 2015

J Pediatr Rev

View full text Add to dashboard Cite

Context: Chronic inflammatory demyelinating polyradiculopathy (CIDP) is an acquired and autoimmune neuropathy, characterized by a chronic, rapidly progressive, symmetric weakness. In children, abnormal gait is as a first symptom of muscle weakness. Evidence Acquisition: The diagnosis of CIDP is on the basis of clinical characteristics, electrodiagnostic that shows the severity of the disease, lumbar puncture and spine magnetic resonance imaging (MRI). Results:The first-line treatments in childhood CIDP are intravenous immunoglobulin (IVIG), corticosteroids, and plasmapheresis. Response to first-line therapies is usually satisfactory; nevertheless, recommendations regarding the choice of second-line therapy can only be prepared on the basis of the existing practice described in some of the case reports. Conclusions: This review demonstrated the clinical presentation, diagnosis, and treatment of childhood CIDP.

show abstract